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Since the pseudorabies virus (PRV) genome encodes for a single immediate-early protein, IE180, we
reasoned that this strong transactivating protein could represent a key regulatory switch that could be
genetically manipulated in order to alter its tropism towards cancer cells. We therefore initiated studies
to test whether the human telomerase reverse transcriptase (hTERT) and carcinoembryonic antigen
(CEA) tumor promoters could functionally replace the IE180 promoter. We show that both promoters can
functionally substitute the IE180 promoter in plasmid constructs and recombinant viruses, and observed
that IE180 differentially auto-regulated each promoter tested, with PRV IE180 negatively regulating the
hTERT promoter but positively hyper-activating the CEA promoter. Interestingly, we also observed that
the recombinant PRV-TER and PRV-CEA viruses preferentially replicated in diverse cancer cell lines
compared to control non-cancer cells, and the PRV-CEA was capable of additionally inducing a profound
apoptotic phenotype which we correlated to the overexpression of IE180.
& 2015 Elsevier Inc. All rights reserved.Introduction
The Herpesviridae family is divided into the three subfamilies
alpha-, beta-, and gammaherpesvirinae. The alphaherpesvirinae
subfamily includes herpes simplex virus types 1 and 2 (HSV-1 and
HSV-2), varicella-zoster virus (VZV), pseudorabies virus (PRV),
equine herpesvirus (EHV1), and bovine herpesvirus 1 (BHV1)
(Pellet and Roizman, 2007). Productive infection of cells by
members of the alphaherpesvirinae subfamily is typiﬁed by a short
reproductive cycle that can be subdivided into three temporally
regulated phases, immediate-early (IE or α), early (E or β), and late
(L or γ). IE genes are the ﬁrst viral genes expressed at the mRNA
level after infection, and they are expressed even in the presence
of inhibitors of cell protein synthesis. This suggests that only host
factors are required for their expression. Expression of E genes
during infection is dependent on IE proteins while expression of L
genes is dependent on DNA replication (Roizman et al., 2007).
HSV-1 has six IE genes: α0, α4, α22, α27, α47 and US1.5, which
encode infected-cell proteins (ICPs) 0, 4, 22, 27, 47 and US1.5és).respectively. ICP4 is the major viral regulatory protein essential for
the replicative cycle of HSV-1 (Roizman et al., 2007). In compar-
ison, PRV has only one IE gene which encodes for the IE180 protein
(Ihara et al., 1983; Mettenleiter, 2000; Tombácz et al., 2009). Both
ICP4 and IE180 therefore represent critical viral transactivator
proteins necessary for replication initiation via regulation of viral
gene expression, either positively or negatively (Ihara et al., 1983;
Leopardi et al., 1995). In addition, these proteins also show a high
level of autoregulation and have been shown to inﬂuence not only
gene expression of other viruses but also the promoters of mam-
malian cells (Green et al., 1983; Wu and Berk, 1988; Yuan et al.,
1989; Wong et al., 1997; Martin et al., 1990).
Oncolytic virotherapy is an emerging ﬁeld in which replicative
competent modiﬁed viruses are used to treat diseases, such as cancer.
HSV-1 has emerged as a very promising candidate in oncolytic vir-
otherapy because of our indepth knowledge and understanding of its
genome and due to the fact that HSV-1 exerts a generally moderate
pathogenicity in humans (Campadelli-Fiume et al., 2011). PRV has also
been suggested as an oncolytic agent for human tumors as it shares
the same advantages described for HSV-1, but at the same time has
additional inherent advantages including the absence of virulen-
ce, recombination and seroprevalence in the human population
L. Lerma et al. / Virology 488 (2016) 9–1910(Sawitzky, 1997; Boldogköi et al., 2002; Prieto et al., 2002; Boldogköi
and Nogradi, 2003; Wollmann et al., 2005). In general, the success of
oncolytic therapy is directly linked to the capacity of the virus in
question to speciﬁcally replicate in cancer cells. The most established
strategy for post-entry restriction of gene expression or viral oncolysis
is transcriptional regulation (Dorer and Nettelbeck, 2009). For tran-
scriptional regulation of oncolytic virus replication, promoters of
essential viral genes have been replaced with speciﬁc cellular pro-
moters that are only active or hyperactive in cancer cells. For example,
PRV recombinant mutants carrying glycoprotein D and HSV-1 thymi-
dine kinase genes under transcriptional control of the human HER-2/
neu promoter have been studied in bladder cancer cells (Shiau et al.,
2007). Due to the strict temporal regulation of herpes virus replication,
tight transcriptional regulation can be theoretically achieved by pla-
cing an essential IE protein (e.g. ICP4 and IE180) under the control of
tumor-speciﬁc promoters; however, it cannot be ignored that IE pro-
teins themselves can auto regulate both viral and mammalian pro-
moters. Thus, an important initial step that needs to be examined,
even before constructing herpes-based oncolytic vectors, is the effect
that such gene modiﬁcations can have on viral replication and/or
cellular functions (e.g. apoptosis).
In the present study we initiated experiments to primarily and
directly address the aforementioned caveat: can a tumor speciﬁc
promoter control IE180 expression and does IE180 in turn auto
regulate these promoters. CEA is a cell membrane-bound glyco-
protein and a member of the immunoglobulin supergene family.
Initially believed to be an oncofetal antigen, it has also been
observed to be expressed in normal adult tissue (Hammarstrom,
1999). hTERT, the catalytic subunit of telomerase, is repressed in
somatic tissues but is up regulated in more than 90% of human
cancers (Shay and Bacchetti, 1997; Liu et al., 2004). Utilizing these
two promoters, we analyzed the capacity of both mammalian
promoters to control viral IE expression and at the same timeFig. 1. hTERT and CEA promoter-mediated IE180 expression. Panel A. Hela Tet-Off cells w
pAZT180 (lane C), pATER180 (lane D), pACEA180 (lane E), ptetICP4lac (lane H) or pEGFP
buffer and Western blot analysis was performed for IE180, HSV-1 ICP4 or Actin, the l
Technologies) (lane F) was included. Panel B. hTERT and CEA promoter-mediated IE180
fection of pATER180 (4 μg), pACEA180 (4 μg), and pAZT180 (4 μg), with pZGF-SD4 (1 μg),
EGFP protein expression was determined by ﬂow cytometry 24 h posttransfection. pEGF
HSV-1 ICP4 protein expressed by ptetICP4lac plasmid was studied by viral transactivatio
R120vGF virus (MOI of 0.05 TCID50/cell), and EGFP protein expression was determined b
(error bars) from three independent experiments.determined the capacity of the PRV IE180 and HSV-1 ICP4 proteins
to autoregulate these promoters. Herein we show that PRV IE180
protein expression can be governed by CEA and hTERT human
tumor-speciﬁc promoters, as both promoters can functionally
substitute the IE180 promoter in PRV-CEA and PRV-TER recombi-
nant viruses. Surprisingly, we observed differences between pro-
moter activity, the capacity of viral IE proteins to differentially
autoregulate the promoters tested and a speciﬁc apoptotic phe-
notype induced by IE180 when under the control of the CEA
promoter. These data therefore demonstrate the capacity of herpes
IE proteins to auto regulate their own expression regardless of the
promoter driving their transcription, and at the same time show a
previously unrecognized pro-apoptotic capacity associated with
IE180 overexpression, a property that could be potentially
exploited to target cancer cells if developing PRV-based oncolytic
vectors.Results
Analysis of EGFP expression under the control of the hTERT and CEA
promoters
The behavior of the hTERT and CEA promoter constructs was
ﬁrst analyzed by assessing, in parallel, the expression of IE180
protein levels and its activity using EGFP as a surrogate marker of
gene transactivation. Plasmids containing the hTERT and CEA
promoters, including mRNA leader regions of 62 nt and 110 nt,
respectively, driving the IE180-coding sequence were constructed
and the ability of the tumor promoters to drive IE180 expression
was assayed by western blot analysis (Fig. 1, panel A), and their
activity was determined by assessing the transactivation of the gG
promoter in the presence of the IE180 protein via the expression ofere mock transfected (lanes A and G) or transfected with 5 μg of pRIE180 (lane B),
N1 (lane I) plasmids. Protein lysates were collected at 48 h posttransfection in RIPA
atter serving as a loading control. Novex sharp pre-stained protein standard (Life
expression were additionally evaluated in parallel transactivation assays. Cotrans-
produces transactivation of the gG promoter resulting in increased EGFP expression.
P-N1 (1 μg) and pUC18 (1 μg) were included as transfection controls. The activity of
n in HeLa Tet-Off cells transfected with 5 μg of ptetICP4lac DNA and infected with
y ﬂow cytometry 24 h p.i. Each value represents the mean and standard deviation
Fig. 2. Induction of EGFP expression from the hTERT and CEA promoters mediated
by PRV IE180 and HSV-1 ICP4 proteins. Panel A. The inﬂuence of PRV IE180 or HSV-
1 ICP4 on the activation of the hTERT promoter (plasmid pZTERGF, 2 μg) was stu-
died in Hela Tet-Off cells by co-transfection with the plasmid pAZT180 (2 μg), which
expresses IE180, or with ptetICP4lac (2 μg), which expresses ICP4. Plasmid pZTERGF
expresses EGFP under the control of the hTERT promoter. EGFP protein expression
was determined by ﬂow cytometry 24 h posttransfection. Each value represents the
mean and standard deviation (error bars) from three independent experiments.
Panel B. The inﬂuence of PRV IE180 or HSV-1 ICP4 on the activation of the CEA
promoter (plasmid pACEA-FG (2 μg) was studied in Hela Tet-Off cells by co-trans-
fection with the plasmid pAZT180 (2 μg), which expresses IE180, or with ptetIC-
P4lac (2 μg), which expresses ICP4. Plasmid pACEA-FG expresses EGFP under the
control of CEA promoter. EGFP protein expression was determined by ﬂow cyto-
metry 24 h posttransfection. Each value represents the mean and standard devia-
tion (error bars) from three independent experiments.
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HeLa Tet-Off cells (Fig. 1, panel B). IE180 protein expression from
the CEA promoter with the plasmid pACEA180 (Fig. 1, panel A, lane
E) was 2.3 fold higher than that achieved with the endogenous
IE180 promoter using the plasmid pRIE180 (Fig. 1, panel A, lane B),
while the plasmid pAZT180 that expresses PRV IE180 under the
control of the tetracycline-responsive promoter (Fig. 1, panel A,
lane C) expressed IE180 4.5 fold more than the plasmid pRIE180
(Fig. 1, panel A, lane B). In contrast, while IE180 expression under
the control of hTERT promoter with the plasmid pATER180 (Fig. 1,
panel A, lane D) was functional, IE180 protein levels were 5.6 fold
less than that achieved with the endogenous IE180 promoter using
the plasmid pRIE180 (Fig. 1, panel A, lane B). The activity of IE180
expressed in Hela Tet-Off cells was next assayed by transactivation
of the PRV gG promoter using the plasmid pZGF-SD4, which
expresses EGFP under control of PRV gG promoter (Muñoz et al.,
2010). The transactivation of the gG promoter in the presence of
the IE180 protein, via the expression of EGFP, was quantiﬁed by
ﬂow cytometry (Fig. 1, panel B). The expression of EGFP under the
control of the CMV-IE promoter (plasmid pEGFPN1) was 9.3 fold
higher than when under the control of the gG promoter (plasmid
pZGF-SD4). The transactivation of EGFP expression under the
control of gG promoter, however, increased 5.2 fold when IE180
was produced under the control of the hTERT promoter (plasmid
pATER180) and 6.3 fold under the control of the CEA promoter
(plasmid pACEA180), which correlates well with the robust IE180
protein expression observed using the CEA promoter (Fig. 1, panel
A, lane E) compared to the hTERT promoter (Fig. 1, panel A, lane
D). When compared to the tetracycline-responsive promoter (Ptet)
(plasmid pAZT180) (Fig. 1, panel A, lane C and panel B), however,
the production of IE180 protein and EGFP transactivation with the
two tumor-speciﬁc promoters in Hela Tet-Off cells was lower
(Fig. 1, panel A, lanes D, E and panel B).
Effect of PRV-IE180 and HSV-1-ICP4 proteins on the activity of the
hTERT and CEA tumor-speciﬁc promoters
To examine the role of PRV-IE180 on the activity of the hTERT
and CEA promoters, and to compare the activity of IE180 with that
of the HSV-1-ICP4 protein, EGFP expression assays were per-
formed with reporter plasmids containing the hTERT promoter
fused to the EGFP reporter gene (pZTERGF) (Fig. 2, panel A) or the
CEA promoter fused to the EGFP reporter gene (pACEA-FG) (Fig. 2,
panel B). The expression levels of EGFP were measured by ﬂow
cytometry analysis. Each of these reporter plasmids was co-
transfected into Hela Tet-Off cells alone or with plasmids that
express PRV-IE180 (pAZT180) or HSV-1-ICP4 (ptetICP4lac) proteins
under the control of the tetracycline-responsive promoters. ICP4
expression by the ptetICP4lac plasmid was conﬁrmed by western
blot (Fig. 1, panel A, lane H) and its activity validated by positive
transactivation of the ICP4 deﬁcient GFP-expressing virus R120vGF
(Fig. 1, panel B). Compared to control samples, the presence of the
HSV-1 IE protein ICP4 increased EGFP expression from the hTERT
promoter 2.5 fold (Fig. 2, panel A) and 3.2 fold from the CEA
promoter (Fig. 2, panel B). Interestingly, the presence of the PRV
IE180 increased EGFP expression from the CEA promoter 4.8 fold
(Fig. 2, panel B), but reduced EGFP expression from the hTERT
promoter 3.0 fold (Fig. 2, panel A). Importantly, this inhibitory
phenotype could be reproduced in a parallel assay where IE180
was expressed from its own viral promoter using the plasmid
pRIE180 (Fig. 3). Speciﬁcally, while IE180 transactivated the PRV
DNA polymerase (pol) (UL30 gene) (p30GF plasmid) and gG
(pZGF-SD4 plasmid) promoters by 7.2 fold, and 6.6 fold, respec-
tively, IE180 again reduced hTERT promoter activity by 2.4 fold
(Fig. 3). These results demonstrate that the IE180 protein represses
the hTERT promoter but hyper-activates the CEA promoter. Inaddition, these data are in concordance with the IE180 western
blot results observed with the pATER180 and pACEA180 plasmids
(Fig. 1, panel A) in which IE180 protein expression driven by
pACEA180 (Fig. 1, panel A, lane E) was 2.3 fold higher compared to
levels achieved with the endogenous viral IE180 promoter, using
the plasmid pRIE180 (Fig. 1, panel A, lane B), while IE180 protein
expression driven by the hTERT promoter, with the plasmid
pATER180 (Fig. 1, panel A, lane D), was 5.6 fold less compared to
pRIE180 (Fig. 1, panel A, lane B).
Expression of PRV IE180 under the control of hTERT and CEA tumor
promoters in recombinant pseudorabies viruses
We next assessed the replication of recombinant PRV viruses in
which the hTERT or CEA human tumor promoters were used to
drive IE180 expression in lieu of its endogenous viral promoter.
The transfection of PBAC90 with the hTERT-IE180 cassette of
pOTER180-N or the CEA-IE180 cassette of pOCEA180-N into U2OS
cells resulted in the production of PRV-TER and PRV-CEA viruses,
respectively. Replacement of the PRV IE180 promoter with the
hTERT or CEA promoters in the PRV recombinants was conﬁrmed
by PCR characterization of packaged viral DNA from PRV-TER, PRV-
CEA, the parental virus vBecker2 and PBAC90 (Fig. 4, panel A and
B). Speciﬁc primers for each promoter P180-S (PIE180), TERT-2D
(PhTERT), CEA-S (PCEA) and 180-AS (coding sequence of IE180 gene)
were used for ampliﬁcation (Table 1). The speciﬁcity of the
ampliﬁcation products was conﬁrmed by DNA size resolution on a
1% agarose gel: 1201 bp for PIE180-IE180, 710 bp for PhTERT-IE180
and 636 bp for PCEA-IE180 cassettes and 523 bp for DNA poly-
merase (UL30), which was used as a reference (Fig. 4, panel B).
Fig. 3. Induction of EGFP expression from the hTERT promoter mediated by PRV IE180. The inﬂuence of PRV IE180, expressed under the control its own promoter (plasmid
pRIE180), on the activation of the hTERT promoter (plasmid pZTERGF, 2 μg), PRV gG promoter (plasmid pZGF-SD4) and DNA polymerase (UL30) promoter (plasmid p30GF,
2 μg) was evaluated by co-transfection of pRIE180 (2 μg) with pZTERGF (2 μg) or pZGF-SD4 (2 μg) plasmids in Hela Tet-Off cells. EGFP protein expression was determined by
ﬂow cytometry 24 h posttransfection. Each value represents the mean and standard deviation (error bars) from three independent experiments.
Fig. 4. Characterization of PRV-TER and PRV-CEA recombinant viruses. Panel A. Schematic diagram of the linear genomes of PBAC90 and the recombinant viruses vBecker2,
PRV-TER, PRV-CEA, indicating IE180 gene copies (arrows), the pac1 (solid circle) and pac2 (bold star) packaging sequences, insertion of F BAC replicon (F) (solid rectangle) and
genes conferring antibiotic resistance, tetracycline (Tc) and Zeocin (ZR). Panel B. PCR ampliﬁcation of the viral DNA polymerase (UL30) (DNA size 523 bp), IE180 (Pr-cs) (DNA
size 1201 bp), PhTERT-IE180cs (DNA size 710 bp), PCEA-IE180cs (DNA size 636 bp) cassettes from vBecker2 (lane A), PBAC90 (lane B), PRV-TER (lane C) and PRV-CEA (lane D).
Negative PCR control without DNA (lane E). PCR was carried out using speciﬁc primers P180-S, TERT-2D, CEA-S and 180-AS for the IE180 cassette and DNApol-D and DNApol-
R primers for the UL30 gene. A 1 Kbp DNA ladder was used as DNA size control (Invitrogen) (lane L). PCR products were separated by gel electrophoresis in 1% agarose gel.
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panel B, lane C), PRV-CEA (Fig. 4, Panel B, lane D) and vBecker2
(Fig. 4, Panel B, lane A) by using speciﬁc primers for each promoter
but not from the PBAC90 (Fig. 4, Panel B, lane B).
IE180 mRNA expression from these recombinant viruses was
then analyzed by quantitative real-time RT-PCR (RT-qPCR) in U2OS
cells infected at a MOI of 0.1 TCID50/cell. Total RNA was harvested
at 12 h and 24 h post-infection (p.i.) and mRNA expression was
analyzed by RT-PCR and qPCR by using the IE180 speciﬁc primers
q180-S and q180-AS (Table 1). β-actin was used as reference cell
gene for RTqPCR analyses (Table 1). At 12 h p.i. IE180 mRNA
expression in U2OS cells after PRV-TER infection was reduced by
14% compared to cells infected with vBecker2, while at 24 h p.i. a
14.1 fold increase in IE180 mRNA expression was observed (Fig. 5,
panel A). In contrast, IE180 mRNA expression in U2OS cells
infected with PRV-CEA increased 31.7 fold at 12 h p.i. compared to
cells infected with vBecker2 and 32.5 fold at 24 h p.i. (Fig. 5, panel
A). This IE180 mRNA overexpression by PRV-CEA at 12 h and 24 h
p.i. parallels the IE180 protein detection observed by western
blot (Fig. 5, panel B, lanes E and J). The 12 h p.i. results are inconcordance with the transfection-based studies detailed above
(Figs. 1 and 2) where the presence of IE180 induces the activity of
the CEA promoter but reduced the activity of the hTERT promoter.
At 24 h p.i., however, the down-regulation of the hTERT promoter
by the IE180 protein reversed but the overall levels of IE180 mRNA
(Fig. 5, panel A) and protein (Fig. 5, panel B) were consistently
lower than those achieved with PRV-CEA.
Characterization of PRV-TER and PRV-CEA: Analysis of apoptosis
induction
To characterize the growth of PRV-TER and PRV-CEA in vitro,
we determined the yield of progeny virus in non-cancer cells (FP7,
human lung ﬁbroblast cell line) and cancer cells (U2OS, human
osteosarcoma cell line; Hela, human cervix carcinoma cell line;
and HT29, human colon adenocarcinoma cell line). Viral yield of
wild-type PRV vBecker2 harvested from FP7 and U2OS cells were
similar and in the order of 6–7 logs TCID50 (Fig. 6, panel A). In
contrast, infection of FP7 control cells with PRV-TER and PRV-CEA
yielded titers of 2.7 and 3.1 log, respectively, approximately 1000
Table 1
Oligonucleotide primers and size of DNAs ampliﬁed by PCR and RT-PCR. The pri-
mers were constructed in promoter (Pr), mRNA leader region (L) or coding
sequence (cs) of the genes.
Gene primer Sequence PCR DNA
size (bp)
UL30 (cs) DNApol-D 50-GTGGAGGTCAACTGCACG-30 523
DNApol-R 50-GCGACGGCGTACATGTCC-30
UL30 (Pr) PRPol-S 50-CTCGAGCAGCGCCAGCAGG-30 398
PRPol-AS 50-CCATGGCTCGTCCCACG-30
IE180 (Pr-
cs)
P180-S 50-TCTGATTGGCTCGCTAGC-30 1021
180-AS 50-GGCCGAAGAGGAGATCCTCG-30
hTERT (Pr) TERT-2D 50-CGCGTCCGGACCTGGAGG-30 553
TERT-2R 50-GCGCCATGGCGGGGGTGG-30
CEA (Pr) CEA-S 50-CTCGAGCCACCTCTGTCACC-30 482
CEA-AS 50-CCATGGTCTCTGCTGTCTGC-30
hTERT(Pr)-IE180 (cs)
TERT-2D 50-CGCGTCCGGACCTGGAGG-30 710
180-AS 50-GGCCGAAGAGGAGATCCTCG-30
CEA(Pr)-IE180 (cs)
CEA-S 50-CTCGAGCCACCTCTGTCACC-30 636
180-AS 50-GGCCGAAGAGGAGATCCTCG-30
GAPDH (cs) GAPDH-S 50-CCACCCATGGCAAATTCC-3 595
GAPDH-AS 50-TCTAGACGGCAGGTCAGG-3
qPCR
IE180 (cs) q180-S 50-CGCCCTTCGAGACCAGCGT-30 122
q180-AS 50-GAAGCCGACGATCTCCACCGC-30
hTERT (L)-IE180 (cs)
L-hTERT 50-TGCTGCGCACGTGGGAAGC-30 207
180-AS 50-GGCCGAAGAGGAGATCCTCG-30
CEA (L)-IE180 (cs)
L-CEA 50-AGCTCTTCTCCACAGAGG-30 208
180-AS 50-GGCCGAAGAGGAGATCCTCG-30
Hu β-actin Huß-actin
For
50-GCGAGCACAGAGCCTCGCCTT-30 125
Huß-actin
Rev
50-CATCATCCATGGTGAGCTGGCGG-30
Fig. 5. IE180 expression under the control of hTERT and CEA promoters in PRV-TER-and
with PRV-TER, PRV-CEA and vBecker2 at a MOI of 0.1 TCID50/cell, cells were harveste
IE180 mRNA was quantiﬁed by RTqPCR using IE180 speciﬁc primers and values are norm
with vBecker2 at 24 h p.i. was increased 8.93 fold in relation to 12 h p.i. Each value
experiments. Panel B. Expression of IE180 protein by PRV-TER and PRV-CEA recombinant
TER (lane D and I)) and PRV-CEA (lane E and J) at a MOI of 0.1 TCID50/cell and IE180 pr
standard (Life Technologies) (lane A and F) was included.
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viral yields were 5.8 and 4.4 log, respectively (Fig. 6, panel A),
suggesting that the replication of the recombinant PRV viruses is
more efﬁcient in cancer cells. To determine whether the replicative
potential of PRV-TER and PRV-CEA is indeed greater in cancer cells,
we measured the viral yields of these recombinant viruses in two
additional cancer cell lines. Viral yield of vBecker2 harvested from
FP7, Hela and HT29 were similar across cell lines, in the order of 6–
7 log TCID50 and comparable to the levels determined in U2OS
cells (Fig. 6, panel B). In contrast, but similar to what was observed
in U2OS cells, infection of the Hela and HT29 cancer cell lines with
PRV-TER or PRV-CEA yielded titers in the order of 2–3 logs TCID50
higher than in FP7 cells (Fig. 7, panel B). The infection of FP7 cells
with PRV-TER or PRV-CEA yielded titers of 2.7 log and 3.1 log,
respectively, at least 1000-fold less virus compared to the parental
virus vBecker2 which yielded a titter of 6.3 log TCID50 (Fig. 6,
panels A and B).
Interestingly, while PRV-CEA replicated more efﬁciently in
cancer cells versus non-cancer cells, PRV-CEA viral yield in U2OS
cells was 21 fold less than PRV-TER. We also observed that U2OS
cells infected with PRV-CEA were morphologically different than
U2OS cells infected with vBecker2 or PRV-TER. While vBecker2 or
PRV-TER induced typical cytopathic effect, PRV-CEA-infected U2OS
cells showed pronounced cytoplasmic blebbing (Fig. 6, panel B), a
phenotype consistent with induced apoptosis (Allen et al., 1997).
Thus, we reasoned that the lower replication of PRV-CEA com-
pared to vBecker2 or PRV-TER may be a causative effect of apop-
tosis induction. To test this hypothesis, we studied apoptosis
induction in U2OS cells infected with viruses vBecker2, PRV-TER or
PRV-CEA at a MOI of 0.2 TCID50/cell. After 24 h p.i., apoptosis was
assessed by annexin-V-FITC staining followed by ﬂow cytometric
analysis. The percentage of late apoptotic cells with vBecker2 and
PRV-TER viruses were 0.77% and 0.51% respectively (Fig. 7, panelsPRV-CEA-infected cells. Panel A. IE180 mRNA expression. U2OS cells were infected
d at 12 h (open bar) and 24 h p.i. (solid bar) and RNA was isolated and puriﬁed.
alized to β-actin mRNA values. IE180 mRNA expression in U2OS cells after infection
represents the mean and standard deviation (error bars) from two independent
viruses. U2OS cells (lane B and G) were infected with vBecker2 (lane C and H), PRV-
otein expression was determined 12 and 24 h p.i. Novex sharp pre-stained protein
Fig. 6. Wild-type PRV vBecker2, PRV-TER and PRV-CEA viral yields in infected mammalian cells. FP7 and U2OS cells were infected at a MOI of 0.2 TCID50/cell, washed to
remove unadsorbed virus, and incubated for 48 h at 37 °C. Virus yield was determined from total lysates of infected cells. Each value represents the mean and standard
deviation (error bars) from three independent experiments (panel A). Virus yields determined, as described above, in Hela and HT29 cells (panel B). Infected and uninfected
U2OS cells were examined by optical microscopy at 48 h p.i. (panel C).
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1.77% for PRV-TER and 1.36% for vBecker2. Interestingly, and in line
with our morphological observations, the percentage of late
apoptotic cells after PRV-CEA virus infection reached 3.55% com-
pared to 0.25% in mock-noninfected cells (Fig. 7, panels A and B ).
While these results suggest apoptotic induction in PRV-CEA
infected cells, we also assessed poly-(ADP ribose) polymerase
(PARP) cleavage in infected cells, an additional indicator of apop-
tosis. The cleavage of PARP is catalyzed by caspase-3 in the later
events of apoptosis and is related to depletion of NAD and ATP
during apoptosis (Boulares et al., 1999). The presence of a cleaved
PRAP protein product of 89 kDa (Fig. 7, panel C) is a well-known
apoptotic hallmark. As expected, we observed cleaved PRAP in
U2OS cells infected with PRV-CEA at 12 h (Fig. 7, panel C, lane E)
and 24 h (Fig. 7, panel C, lane J) p.i., which directly correlated with
IE180 expression (Fig. 5, panel B, lanes E and J respectively). These
results show that over-expression of IE180 in U2OS cells infected
at 12 h p.i. with PRV-CEA (Fig. 5 panel A, and panel B, lane E) and
not vBecker2 ( Fig. 5, panel B, lane C) or PRV-TER (Fig. 5, panel B,
lane D) clearly results in apoptosis (Fig. 7, panel C, lane E), which is
in line with studies where the IE180 protein was suggested as a
possible inducer of apoptosis (Tomioka et al., 2008, 2013).
Importantly, this apparent IE180-mediated apoptotic phenotype
was additionally conﬁrmed in PK15-IE180 cells, which stably
express IE180 under the control of the tetracycline-responsive
promoter (Ptet) (Oyibo et al., 2014). In the presence of doxycycline,
the expression of IE180 induced early and late apoptosis at 48 h
post induction in 1.78% and 4.63% of cells, respectively, compared
to 0.75% and 1.29% in mock non-induced cells (Fig. 8, panels A and
B). In addition, the induction of IE180 expression at 48 h, in the
presence of doxycycline, was conﬁrmed by western blot anal-
ysis (Fig. 8, panel C, lane C) and its activity conﬁrmed bytransactivation of the gG promoter of plasmids pZGF-SD4 and
pOGF-SD4 (Fig. 8, panel D).Discussion
IE180 has a high level of similarity to the IE proteins of other
alphaherpesviruses such as ICP4 (HSV-1), IE140 (VZV, Varicella-
zoster virus), IE1 (EHV1, equine herpesvirus 1) and p180 (BHV-1,
bovine herpesvirus 1) (Vlcek et al., 1989). Moreover, all of these
viral gene products are multifunctional proteins that share similar
functional domains. They have been divided into ﬁve colinear
regions based on their predicted amino acid sequences, with a
high level of similarity in regions 2 and 4 and little, if any, in
regions 1, 3 and 5 (Cheung, 1989; Wu and Wilcox, 1991). The auto-
regulatory domain, the nuclear localization signal (NLS) and the
transactivation domain (TAD) are located in regions 2 and 4. We
previously described that the IE180 protein of PRV can down-
regulate the transactivation of the HSV-1 ICP4 promoter (Gómez-
Sebastian and Tabares, 2004) and some viral DNA replication was
detected in the presence of IE180 when 293T cells were infected
with HSV-1 d120 strain deﬁcient in ICP4 (Gómez-Sebastian and
Tabares, 2004). This indicates that complementation between the
IE180 protein of PRV and the ICP4 protein of HSV-1 occurs to some
extent, at least up to the early phase of viral replication. The IE
proteins ICP4 and IE180 stimulate transcription from both cellular
and viral genes; however no promoter sequences have been
identiﬁed that are uniquely involved in transcriptional stimulation
(Abmayr et al., 1988). Thus, the different behavior of ICP4 and
IE180 in the activation and repression of the hTERT promoter,
respectively, could be related to interactions with cell factors
involved in transcription, such as TFIID. ICP4 can activate tran-
scription from cellular promoters such as human ubiquitin B
Fig. 7. PRV-CEA virus infection induces apoptosis in U2OS cells. Mock-and vBecker2, PRV-TER and PRV-CEA infected (MOI of 0.2 TCID50/cell) cells were stained with annexin
V-FITC and DAPI and analyzed by ﬂow cytometry. Percentage of live cells (i), percentage of early apoptotic cells (ii), late apoptotic cells (iii) and percentage of dead cells (iv)
are shown (Panel A). Percentages of early (solid bar) and late (open bar) apoptotic cells are summarized. Each value represents the mean and standard deviation (error bars)
from three independent experiments (Panel B). In addition, apoptosis was detected by caspase activation resulting in PARP cleavage in U2OS infected cells 12 h and 24 h p.i.
by western blot analysis using a puriﬁed mouse anti-human PARP (Panel C). Novex sharp pre-stained protein standard (Life Technologies) (lane A and F) was included.
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growth factor-A (VEGF-A) (Wuest et al., 2011). Analogously, the
role of IE180 as a potent transcriptional activator has been estab-
lished and, like most typical cellular activators, IE180 contains a
separate domain for DNA-binding and another for transactivation
(Martin et al., 1990). IE180 can activate transcription from cellular
promoters such as beta-globin and topoisomerase I (Green et al.,
1983; Wong et al., 1997); however, in our study we observed that
it represses the hTERT promoter but hyper-activates the CEA
promoter. Further studies are still needed to dissect this differ-
ential repressive/activating capacity at the molecular level, but in
the context of developing recombinant viruses, our results high-
light the importance of conducting promoter activity studies when
swapping IE promoters out for cellular promoters, such as tumor
speciﬁc promoters. The ICP4 and IE180 gene products are the
major regulatory proteins for the replicative cycle of HSV-1 and
PRV, respectively, affecting viral gene expression either positively
or negatively, including auto regulation (Ihara et al., 1983; Leopardi
et al., 1995). This auto regulation can be interchanged between
both viruses (Gómez-Sebastian and Tabares, 2004) and seems to
play an important role in viral replication. In our study, the sub-
stitution of the IE180 promoter in vBecker2 with the CEA promoter
produced a signiﬁcant overexpression of IE180 at 12 h p.i. due to
hyperactivation of the CEA promoter by the PRV IE180 protein.
This resulted in viral yields 48 h p.i. of 2 logs less than vBecker2,which we attributed to the induction of apoptosis via a IE180-
dependent mechanism although overexpression of IE180 may also
have an inhibitory effect on early protein 0 (EP0) and large latency
transcript (LLT) expression (Ou et al., 2002) with may additionally
diminish viral replication. EP0 activates PRV gene transcription in
combination with the IE180, enhances the synthesis of infectious
virus (Ono et al., 1998) and its mRNA expression is detected in
inverse relationships to IE180 mRNAs expression (Tombácz et al.,
2009), thus over expression of IE180 may also affect alternate
viral-speciﬁc mechanisms that are currently under investigation.
In contrast to PRV-CEA, when the IE180 promoter in vBecker2
was replaced with the hTERT promoter, which is repressed by
IE180 protein, viral production increased approximately one log
compared to PRV-CEA, but unlike the CEA promoter, the hTERT
promoter exhibited IE180-dependent autoregulation, resulting in
less efﬁcient virus production compared to vBecker2. Interest-
ingly, at later time points p.i. there was an apparent loss of hTERT
auto down-regulation in U2OS cells infected with PRV-TER,
which we hypothesize could be related to other viral processes
and kinetic events. Nonetheless, our data show that the exchange
of viral promoters for cellular promoters is feasible but at the
same time subject to numerous regulatory checkpoints, both viral
and cellular, and these processes should be taken into con-
sideration and evaluated when constructing recombinant PRV
vectors. The effects of replacing the IE180 promoter in PRV with
Fig. 8. IE180 protein induces apoptosis of PK15-IE180 cells. PK15-IE180 cells were
cultured in presence or absence of 2 μg/ml doxycycline to induce IE180 expression.
Panel A. Cells were washed in annexin buffer and directly analyzed by ﬂow cyto-
metry after the addition of annexin V-FITC and DAPI. Percentage of live cells (i),
percentage of early apoptotic cells (ii), late apoptotic cells (iii) and the percentage of
dead cells (iv) are shown. Panel B. Columns represents the mean from two inde-
pendent experiments of early (solid bar) and late (open bar) apoptotic cell per-
centages. Panel C. Protein lysates of PK15-IE180 cells in the presence (lane B) or
absence (lane A) of 2 μg/ml doxycycline were collected at 48 h postinduction and
Western blot analysis was performed with 30 μg of protein for PRV IE180 and Actin,
an internal cellular loading control. Panel D. Transactivaton of the gG promoter on
PK15-IE180 cells. PK15-IE180 cells were transfected with pZGF-SD4 or pOGF-SD4
plasmids in the presence or absence of 2 μg/ml doxycycline. EGFP protein expres-
sion was determined by ﬂow cytometry 48 h posttransfection and is expressed as
ﬂuorescence intensity (MFI). Each value represents the mean and standard devia-
tion (error bars) from three independent experiments.
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(CKIV), the bovine cytokeratin VIb gene (CKVIB) or the inducible
promoters drosophila heat-shock gene HSP70 or the tetracycline-responsive promoter (Ptet) have previously been studied (Gla-
zenburg et al., 1992, 1995; Muñoz et al., 2011), and the authors
concluded that the replicative ability and virulence of pseu-
dorabies virus can be inﬂuenced by altering control of IE gene
expression, as may be happening after infection with the
recombinant PRV-CEA virus.
While not the immediate focus of this study, the results pre-
sented here also suggest that PRV-CEA may represent a putative
oncolytic vector. First, the IE180 promoter can be successfully
replaced with the CEA tumor promoter, IE180 mRNA is expressed
to high levels from this promoter and most importantly, IE180
does not negatively auto regulate the CEA promoter as is the case
with the hTERT promoter. Second, PRV-CEA replication was more
efﬁcient in the cancer cell lines U2OS, Hela and HT29 compared to
control FP7 human ﬁbroblasts. This signiﬁcant difference would
suggest that PRV-CEA preferentially replicates in cancer cells,
where CEA promoter activity is presumably hyper activated due to
the cellular environmental context. It would be interesting to see if
this apparent speciﬁcity for cancer cells holds up across a larger
panel of cancer cell lines from different tumor types. Lastly, and in
line with the hyper activation of the CEA promoter in U20S cells
resulting in increased IE180 mRNA, we observed a clear induction
of apoptosis in cancer cells. This phenotype was clearly due to
IE180 over expression since a similar phenotype was observed
when IE180 was conditionally over expressed in PK15-IE180 por-
cine cells. These results are in concordance with studies performed
in transgenic mice expressing PRV IE180, where it was suggested
that IE180 over expression induced apoptosis although it was not
ofﬁcially demonstrated (Tomioka et al., 2008, 2013). It is inter-
esting that over expression of IE180 induces apoptosis, while other
viral immediate-early proteins, like ICP4 have been proposed to
have anti-apoptotic functions (Leopardi and Roizman, 1996; Peri
et al., 2011). Indeed IE180 suppresses phosphorylation of transla-
tion initiation eIF2a factor (Van Opdenbosch et al., 2012), which
could play a role in its capacity to induce apoptosis (Jiang andWek,
2005). Nonetheless this apparent pro-apoptotic function may
represent an added advantage in the context of PRV-based onco-
lytic vectors, in which PRV could be genetically manipulated to
preferentially initiate a lytic replication cycle in tumor cells via
CEA promoter transcriptional regulation and at the same time
induce apoptosis of cancer cells a “missile and warhead” approach.
PRV has also been put forth as a suitable oncolytic agent for
human tumors due to the absence of virulence, although PRV
replicates efﬁciently in human cell lines (Sawitzky, 1997; Fernán-
dez et al., 1999; Boldogköi et al., 2002; Prieto et al., 2002; Bol-
dogköi and Nogradi, 2003; Wollmann et al., 2005; Shiau et al.,
2007). In our studies, PRV-TER and PRV-CEA recombinants showed
signiﬁcant attenuation in human cells as its replication was at least
1000-fold less compared to the parental virus vBecker2. Thus,
there still remains room for signiﬁcant improvement of PRV-CEA
as a putative oncolytic virus. For example, further studies aimed at
improving biosafety [e.g. increasing ganciclovir sensitivity of these
viruses by incorporating HSV-1 TK gene into PRV viral genome
(Gomez-Sebastián and Tabarés, 2004) and increasing cancer cell
speciﬁcity are still needed and are in progress.Conclusions
In the present study we show that PRV IE180 protein expres-
sion can be governed by CEA and hTERT human tumor-speciﬁc
promoters, as both promoters can functionally substitute the IE180
promoter in PRV-CEA and PRV-TER recombinant viruses. IE180
showed negative regulation on the hTERT promoter but positive
hyperactivation of the CEA promoter. PRV-TER and PRV-CEA
viruses preferentially replicated in several human cancer cell
L. Lerma et al. / Virology 488 (2016) 9–19 17lines compared to control non-cancer cells, and PRV-CEA was also
capable of inducing apoptosis which we correlated to the over-
expression of IE180. These data therefore support the further
development of PRV-based oncolytic vectors and at the same time
show a previously unrecognized pro-apoptotic capacity associated
with IE180 overexpression, a property that could be additionally
exploited to target cancer cells.Material and methods
Viruses and cells
The Hela human cervix carcinoma cell line, HT29 human colon
adenocarcinoma cell line, U2OS human osteosarcoma (osteoblast)
cell line and the FP7 human lung ﬁbroblast cell line were grown in
Dulbecco's modiﬁed Eagle's minimal essential medium (DMEM),
supplemented with 10% fetal calf serum. HeLa Tet-Off cells
(Clontech) were grown in DMEM containing 10% fetal bovine
serum supplemented with 100 μg/ml Geneticin (Life Technolo-
gies). PK15-IE180-expressing cells (Oyibo et al., 2014) were grown
in DMEM containing 10% fetal bovine serum and supplemented
with 500 μg/ml Geneticin to select for cells possessing the PRV
IE180 transgene. When necessary, 2 μg/ml doxycycline (Clontech)
was added to the medium to induce expression of the IE180 gene.
The parental virus vBecker2 was generated by transfection of
pBecker2 plasmid (Smith and Enquist, 2000) into Hela Tet-Off
cells. The recombinant HSV-1 R120vGF virus expresses EGFP and is
deﬁcient in ICP4 (Bello-Morales et al., 2014) and was generated in
E5 cells as per standard protocols.
Cloning of hTERT and CEA tumor promoters
DNA fragments of hTERT and CEA promoters upstream of the
initiating ATG codon were ampliﬁed by PCR and characterized by
DNA sequencing performed by an automated DNA sequencing
system from Applied Biosystem. The core hTERT promoter
sequence (Horikawa et al., 1999) (nucleotides-543 to þ6 from the
ATG initiation codon) was ampliﬁed from Hela cell DNA by PCR
(Muñoz et al., 2011) using primers TERT-2D and TERT-2R (Table 1)
and cloned into pGEM-Teasy (Promega), giving rise to the plasmid
pGTER1P. The hTERT promoter generated by PCR was mutated to
include an NcoI restriction site at the ATG initiation codon (primer
hTERT-2R). The core CEA promoter (nucleotides-474 to þ4 from
the ATG initiation codon) (Schrewe et al., 1990) was ampliﬁed
from human amnion cell DNA by PCR (Muñoz et al., 2011) using
primers CEA-S and CEA-AS (Table 1) and cloned into pGEM-Teasy
(Promega), giving rise to the plasmid pGCEA-A. The CEA promoter
generated by PCR was mutated to include an NcoI restriction site at
the ATG initiation codon (primer CEA-AS).
Plasmid constructs
Plasmids used in transient expression assays included the fol-
lowing: (i) pRIE180-expresses PRV IE180 under the control of the
natural IE180 promoter (Muñoz et al., 2010). (ii) pAZT180-
expresses PRV IE180 under the control of the tetracycline-
responsive promoter (Ptet) (Muñoz et al., 2011). (iii) ptetICP4lac-
expresses HSV-1 ICP4 under the control of the tetracycline-
responsive promoter (Ptet). The ICP4 coding sequence was
ampliﬁed by PCR and cloned into pUHD10-1 (Gossen and Bujard,
1992) blunted at the EcoRI and BamHI sites. The tetO-ICP4 frag-
ment was then excised by XhoI/HindIII digestion and cloned into
the HindIII site of pHSVpuc (Geller et al., 1993). (iv) pZGF-SD4-
includes the promoter-regulatory region of the gG gene, the EGFP-
coding sequence, and the SV40 polyadenylation signal, ﬂanked bythe PRV homologous recombination regions (Muñoz et al., 2010).
(v) p30GF – was constructed by replacing the gG promoter (XhoI-
NcoI fragment, NcoI includes translation initiation ATG codon) in
pSD4-AG with the UL30 promoter (XhoI-NcoI fragment, NcoI site
includes the translation initiation ATG codon of UL30). The XhoI-
NcoI 400 bp fragment of the UL30 promoter was ampliﬁed by PCR
using primers PRPol-S and PRPol-AS (Table 1). (vi) pATER180 –
expresses IE180 under the control of the hTERT promoter (PTER)
and was constructed by replacing the tetracycline-responsive
promoter (Ptet) (EcoRI blunt-NcoI fragment) in pAZT180 with the
hTERT promoter (HindIII blunt-NcoI fragment of pGTER1P). (vii)
pACEA180 – was constructed by replacing the tetracycline-
responsive promoter (Ptet) promoter (EcoRI blunt-NcoI fragment)
in pAZT180 with the CEA promoter (XhoI blunt-NcoI fragment of
pGCEA-A). (viii) pZTER-GF – was constructed by replacing the gG
promoter (StuI-NcoI fragment) in pZGF-SD4 with the hTERT pro-
moter (SpeI-NcoI fragment of pGTERT1P). (ix) pACEA-FG – was
constructed by replacing the gG promoter (StuI-NcoI fragment) in
pZGF-SD4 with the CEA promoter (XhoI-NcoI fragment of pGCEA-
A. (x) pOZPAC-GF – was obtained by inserting the NotI fragment of
pORIPAC-GF (Prieto et al., 2002), which includes the EGFP
expression cassette, in the NotI site of the pOZPAC plasmid (Muñoz
et al., 2011). (xi) pOZPACGF-N – was obtained from pOZPAC-GF,
eliminating the NdeI site of the pUC18 vector by blunting the NdeI
site followed by religation. (xii) pOTER180-N and pOCEA180-N –
were obtained by inserting pATER180 and pACEA180 AseI-MluI
fragments in the pOZPACGF-N plasmid digested with AseI-MluI
obtaining pOTER180-N and pOCEA180-N, respectively. The p180FG
SphI-HincII fragment contains the EGFP expression gene under the
control of the PRV IE180 promoter (Muñoz et al., 2010).
Recombinant PRV viruses
The PRV-TER recombinant virus was made by cotransfecting
the ApaLI-KpnI fragment of pOTER180-N (1.5 μg) together with
PBAC90 DNA (Muñoz et al., 2011) (4 μg) into U2OS cells using
Lipofectamine 2000 (Invitrogen), as per the manufacter's protocol.
Positive foci of infection were detected one-week post-transfec-
tion. Analogously, the PRV-CEA recombinant virus was made by
cotransfecting the ApaLI-KpnI fragment of pOCEA180-N (1.5 μg)
together with PBAC90 DNA (Muñoz et al., 2011) (4 μg) into U2OS
cells using Lipofectamine 2000 (Invitrogen). Positive foci of
infection were detected one-week post-transfection. Stocks of
virus were produced by propagation in U2OS cells. PBAC90 is a
non-infectious PRV BAC deﬁcient in the IE180 gene (Muñoz et al.,
2011).
Flow cytometric measurement of EGFP expression
A total of 6105 HeLa Tet-Off cells were seeded into 12.5 cm2
ﬂasks. Cells were transfected with plasmids using Lipofectamine
2000 (Invitrogen), as per the manufacter's protocol, harvested 24 h
posttransfection, ﬁxed with paraformaldehyde, washed once in
PBS, resuspended in 0.7 ml of 1X PBS, and analyzed with a Flow
Cytometer (Cytomics FC500 MPL, Beckman Coulter). The ﬂuor-
escent EGFP protein (excitation: 488 nm, emission: 508 nm) pro-
duced was used to monitor the efﬁciency of expression by ﬂuor-
escence microscopy or ﬂow cytometry. The mean ﬂuorescence
intensity (MFI) was measured.
Western blot analysis
Extracts from transiently transfected Hela Tet-Off cells or U2OS
cells infected with recombinant viruses were lysed in RIPA buffer
(Sigma) supplemented with a Complete, Mini, EDTA-free protease
cocktail inhibitor (Roche) and analyzed by 12% PAGE. Prot-
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(Amersham) in 20 mM Tris–HCl (pH 8.3), 150 mM glycine, 20%
methanol and 0.02% SDS (15 V; 30 min) using a Transblot cell (Bio-
Rad). The membrane was blocked in PBS with 3% BSA (4 °C,
overnight) and then incubated with rabbit polyclonal anti-IE180
(Gómez-Sebastian and Tabares, 2004) (1:200), anti-β-actin
(Thermo Scientiﬁc) (1:1000), or mouse monoclonal anti-ICP4
(Abcam, Cambridge, UK) (1:2000) in blocking solution with
0.05% Tween 20 (4 °C, overnight) with constant rocking. The
membrane was washed extensively in PBS with 0.05% Tween 20
and incubated for 1 h with IgG anti-mouse peroxidase (1:4000;
Sigma) or IgG anti-rabbit peroxidase (1:5000; Sigma) for mouse
monoclonal or rabbit polyclonal antibodies, respectively. Blots
were developed with ECL detection reagents (Amersham) and
exposed to Kodak X-OMAT AR ﬁlm. Densitometric analysis was
performed using Adobe Photoshop CS4 where Actin served as a
normalization control.
Isolation of viral and cellular DNA
Packaged viral DNA was isolated from the cytoplasmic cell
fraction (Prieto et al., 2002). Total DNA from infected cells was
isolated by SDS-proteinase treatment (QF Amp DNA Micro,
Qiagen).
Analysis of nucleic acids by PCR and RT-PCR
Total RNA from U2OS cells infected with PRV recombinants at a
multiplicity of infection (MOI) of 0.1 TCDI50/ml was isolated using
the RNeasy mini kit (Qiagen) or acid guanidinium thiocyanate-
phenol-chloroform extraction (Chomczynski and Sacchi, 1987) and
treated with 4 U/ml DNAse (DNA-free kit, Applied Biosystems,
Ambion). No DNA contamination was found in any of the RNA
preparations by speciﬁc PCR ampliﬁcation of the cellular GAPDH
gene. Reverse-transcription PCR (RT-PCR) was carried out with
2.0 μg of RNA using the First Strand cDNA Synthesis Kit (Roche) to
amplify viral IE180 and cellular GAPDH mRNAs, the latter serving
as an internal control, using the speciﬁc primers listed in Table 1.
The RT-PCR program consisted of: 1 cycle (10 min, 65 °C) of RNA
denaturation, 30 min at 55 °C for retrotranscription and 5 min at
85 °C for RT inactivation. The PCR program consisted of: 1 cycle
(15 min, 95 °C) of DNA denaturation and Taq DNA polymerase
activation, 35 cycles (1 min, 95 °C) of denaturation, 1 min at 53 °C
(50 °C for GAPDH) for annealing, and 1 min at 72 °C for elongation,
and a ﬁnal cycle (10 min, 72 °C) for further elongation. PCR pro-
ducts were analyzed by 1% agarose gel electrophoresis, and the
speciﬁcity of the ampliﬁcation products was conﬁrmed by the size
of the DNA products (Table 1).
Quantitative Real-Time PCR (RTqPCR)
One μg of RNA was reverse-transcribed using the QuantiTect
Reverse Transcription Kit (Qiagen). RTqPCR was performed to
amplify the viral IE180 and cellular β-actin mRNA, the latter ser-
ving as an internal control, using the speciﬁc primers for each
mRNA listed in Table 1. The RTqPCR reactions were performed
with a Real-Time PCR StepOnePlusTM instrument (Applied Bio-
systems) using FAST-SYBR Green (Applied Biosystems) according
to the manufacturer's protocol. The reaction mixture consisted of
1X FAST SYBR Green (Applied Biosystems), sense and antisense
primers each at 0.25 μM, and 15 ng cDNA. Thermal cycling con-
sisted of an initial 10 min denaturation step at 95 °C followed by
40 cycles of denaturation (15 s at 95 °C) and annealing/extension
(1 min at 60 °C).Evaluation of apoptosis
Apoptosis was measured by ﬂow cytometric analysis using the
AnnexinV-FITC (BD) staining kit as per the manufacturer's
instructions. Uninfected and infected U2OS cells were trypsinized
after 24 h p.i., washed with PBS and incubated with Annexin V-
FITC and DAPI solution (Bender MedSystems, Burlingame) in the
dark for 20 min. Afterwards, cells were treated with DAPI and
samples were analyzed by ﬂow cytometry with a FACSCANTO II
cytometer (Becton Dickinson, Mountain View) and data processed
using BD FlowJo 8.7 software. The amount of early apoptosis and
late apoptosis was determined as the percentage of Annexin Vþ/
DAPI and Annexin Vþ/DAPIþ , respectively (Miranda-Lorenzo et
al., 2014). In addition, apoptosis produces caspase activation,
which leads to poly(ADP ribose) polymerase (PARP) cleavage,
which was detected in U2OS infected cells 12 and 24 h p.i. by
western blot analysis using a puriﬁed mouse anti-human PARP
antibody (Cell Signalling, US) (1:1000). Bound anti-PARP was
detected using an anti-mouse peroxidase secondary antibody
(1:4000; Sigma).Acknowledgments
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